Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO
RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September 2023
Commission File Number: 001-41324
(Name of registrant)
1a, 1b Learoyd Road
New Romney TN28 8XU, United Kingdom
principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
On September 20, 2023, Akanda Corp (the “Company”)
issued a press release entitled “Akanda Corp. Announces Signing of Option to Develop Canadian THC and CBD Farming Facility”.
A copy of the please release is filed as Exhibit 99.1 to this Current Report on Form 6-K and is incorporated herein by reference.
release furnished in this report as Exhibit 99.1 shall not be deemed to be “filed” for the purposes of Section 18
of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section.
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|Date: September 20,
AKANDA CORP. ANNOUNCES SIGNING OF OPTION TO
DEVELOP CANADIAN THC AND CBD FARMING FACILITY
Germany & LONDON --(BUSINESS WIRE)-- International medical cannabis company Akanda Corp. (“Akanda”
or the “Company”) (NASDAQ: AKAN, WKN: A3DG83) announces that Akanda (the “Optionee” the “Company”)
and 1107385 B.C. LTD (the “Owner”) have agreed upon terms to purchase farming land and related operations and licenses.
The key deal terms are as follows:
Akanda will issue a non-refundable payment equal
to One Million Eight Hundred Thousand United States Dollars (USD1,800,000) and if paid in common shares of Akanda will be based on formula
to calculate the per share price as set forth in the agreement. The initial payment will be broken up into the First Option Payment, the
Second Option Payment and the Third Option Payment, upon signing, 15 days after signing, 30 days after signing respectively.
This buys Akanda the right to develop the property
for two years. The Company plans during this time period to develop Tetrahydrocannabinol (THC) and CBD facilities at this site. Additional
payments will be made based upon milestones achieved from the development. Additional milestones include THC cultivation, sales of product,
CBD cultivation, and Hemp cultivation. This is similar to a mining agreement where operators buy the right to mine a site. In this case
the Company has purchased the right to develop the farming land.
Further payment milestones include:
|●||Upon approval or a license for THC cultivation on the property from the applicable regulatory authority,
$500,000 will be paid to the Owner.|
|●||Upon sale of ,THC product cultivated from the property, $500,000 will be paid|
|●||Upon Hemp cultivation approval from the application regulatory authority, $750,000 will be paid|
|●||Upon CBD cultivation approval from the application regulatory authority, $750,000 will be paid|
About Akanda Corp.
an international medical cannabis and wellness platform company seeking to help people lead better lives through improved access to high
quality and affordable products. Akanda’s portfolio includes Holigen, a Portugal-based cultivator, manufacturer and distributor
with a prized EU GMP certified indoor grow facility; CanMart, a UK-based fully licensed pharmaceutical importer and distributor
which supplies pharmacies and clinics within the UK. The Company’s seed-to-patient supply chain also includes partnerships
with California-based Cookies, the most globally recognized cannabis company in the world; Cansativa Group, a leading importer
and distributor of medical cannabis in Europe; and Cellen Life Sciences’ Leva Clinic, one of the first fully digital
pain clinics in the UK.
Cautionary Note Regarding Forward-Looking Information and Statements
This press release contains certain "forward-looking information"
within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking
statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995.
Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition,
but instead represent only Akanda's beliefs regarding future events, plans or objectives, many of which, by their nature, are
inherently uncertain and outside of Akanda's control. Generally, such forward-looking information or forward-looking statements
can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect",
"is expected", "budget", "scheduled", "estimates", "forecasts", "intends",
"anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may contain
statements that certain actions, events or results "may", "could", "would", "might" or "will
be taken", "will continue", "will occur" or "will be achieved". Forward-looking information may relate
to anticipated events or results including, but not limited to business strategy, product development and sales and growth plans. The
forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release,
and Akanda does not undertake to update any forward-looking information and/or forward-looking statements that are contained
or referenced herein, except in accordance with applicable securities laws.
Historical Stock Chart
From Nov 2023 to Dec 2023
Historical Stock Chart
From Dec 2022 to Dec 2023